[go: up one dir, main page]

ZA200500108B - Topical treatment of skin diseases. - Google Patents

Topical treatment of skin diseases. Download PDF

Info

Publication number
ZA200500108B
ZA200500108B ZA200500108A ZA200500108A ZA200500108B ZA 200500108 B ZA200500108 B ZA 200500108B ZA 200500108 A ZA200500108 A ZA 200500108A ZA 200500108 A ZA200500108 A ZA 200500108A ZA 200500108 B ZA200500108 B ZA 200500108B
Authority
ZA
South Africa
Prior art keywords
mono
alkyl
aryl
polyunsaturated
ring members
Prior art date
Application number
ZA200500108A
Other languages
English (en)
Inventor
Chris Rundfeldt
Manfred Kietzmann
Joachim Hoppmann
Wolfgang Baeumer
Hildegard Kuss
Norbert Hoefgen
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of ZA200500108B publication Critical patent/ZA200500108B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200500108A 2002-07-11 2005-01-06 Topical treatment of skin diseases. ZA200500108B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39522102P 2002-07-11 2002-07-11

Publications (1)

Publication Number Publication Date
ZA200500108B true ZA200500108B (en) 2005-02-23

Family

ID=30115840

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500108A ZA200500108B (en) 2002-07-11 2005-01-06 Topical treatment of skin diseases.

Country Status (20)

Country Link
US (1) US20040038958A1 (pt)
EP (1) EP1531818A1 (pt)
JP (1) JP2005537262A (pt)
KR (1) KR20050021464A (pt)
CN (1) CN1681500A (pt)
AR (1) AR040647A1 (pt)
AU (1) AU2003254332B2 (pt)
BR (1) BR0312696A (pt)
CA (1) CA2492093A1 (pt)
HR (1) HRP20050133A2 (pt)
IL (1) IL166016A0 (pt)
MX (1) MXPA05000486A (pt)
NO (1) NO20050718L (pt)
NZ (1) NZ537482A (pt)
PL (1) PL375487A1 (pt)
RU (1) RU2005103608A (pt)
TW (1) TW200410690A (pt)
UA (1) UA80711C2 (pt)
WO (1) WO2004006920A1 (pt)
ZA (1) ZA200500108B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US7580380B2 (en) * 2003-05-28 2009-08-25 Artimi Ltd Communications systems and methods
ATE541570T1 (de) * 2004-02-06 2012-02-15 Meda Pharma Gmbh & Co Kg Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
JP4819699B2 (ja) * 2004-02-06 2011-11-24 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
JP4961131B2 (ja) * 2004-10-29 2012-06-27 田辺三菱製薬株式会社 皮膚損傷治療剤
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
PL1971369T3 (pl) 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
CN101370775A (zh) * 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
WO2009025239A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. 新規外用剤
CA2696727A1 (en) 2007-08-17 2009-02-26 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EP3201203B1 (en) 2014-09-29 2021-05-19 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
WO1994024984A2 (en) * 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
DK1076657T3 (da) * 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Also Published As

Publication number Publication date
BR0312696A (pt) 2005-04-26
KR20050021464A (ko) 2005-03-07
PL375487A1 (en) 2005-11-28
CA2492093A1 (en) 2004-01-22
HRP20050133A2 (en) 2005-04-30
IL166016A0 (en) 2006-01-15
AR040647A1 (es) 2005-04-13
AU2003254332B2 (en) 2009-01-08
TW200410690A (en) 2004-07-01
WO2004006920A1 (en) 2004-01-22
NZ537482A (en) 2006-09-29
RU2005103608A (ru) 2005-06-27
US20040038958A1 (en) 2004-02-26
AU2003254332A1 (en) 2004-02-02
CN1681500A (zh) 2005-10-12
NO20050718L (no) 2005-04-01
UA80711C2 (en) 2007-10-25
JP2005537262A (ja) 2005-12-08
MXPA05000486A (es) 2005-07-22
EP1531818A1 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
AU2003254332B2 (en) Topical treatment of skin diseases
Zuberbier et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
Fischer et al. Vitamin D regulating TGF-β induced epithelial-mesenchymal transition
US6403831B1 (en) Substituted benzylidene indenyl formamides, acetamides and propionamides
PT2033635E (pt) Derivados de ácidos gordos de cadeia curta para tratar o prurido
Bäumer et al. AWD 12–281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis
Fujii et al. Characterization of a 2, 4-dinitrochlorobenzene-induced chronic dermatitis model in rats
JPH07258208A (ja) フッ素化ビタミンｄ３誘導体
Bäumer et al. Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis
JP6498195B2 (ja) 代謝疾患を処置するためのｐｐａｒ節約化合物
CA2164955A1 (en) Method for treating hyperkeratosis and diseases mediated by proteases
EP1101496A1 (en) Therapeutic agents for allergic diseases
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
Harada et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models
CN110536688B (zh) 创伤修复促进剂
AU757489B2 (en) Method for inhibiting cytokine production by cells
US20240269138A1 (en) Mmp13 as a therapeutic target for allergic inflammatory diseases
EP3569228A1 (en) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
Allal et al. Long-term 1, 2-dimethylhydrazine triggers pathological remodeling of colon mucosa through repression of sestrin2, nuclear factor (erythroid-derived 2)-like 2, and sirtuin4 stimulating mitochondrial stress and metabolic reprogramming
Parker et al. Ruxolitinib cream ameliorates spontaneous atopic dermatitis in the IL-33 transgenic mouse model
CN119157880A (zh) 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK3激酶抑制剂在治疗特应性皮炎中的应用
WO2023203022A1 (en) Treatment of neutrophilic dermatoses
OA19594A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2001508042A (ja) 相乗的金―含有組成物